Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.
Robertson D, Alvarez E, Steinman L, Hartung H-P, Qian P, Selmaj K, Wray S, Wynn D, Fox EJ, Mok K, et al.
Front Immunol. 2026; 17:1771848. PMID: 42292352.Abstract
